|   | 
                  
                       | 
                      | 
                    
                        
                            
                                | 
                                  
                                 | 
                             
                             |  
                            
                                
                                    
                                        
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ½ºÆÄÅä¹Îĸ½¶(µð½ÃŬ·Î¹Î¿°»ê¿°)   SPATOMIN CAP.  
                    
                 | 
               
              
                
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                         |  
                    
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |                   
                                        | 
                                             | 
                                         
                            
                            
                                         |  
                                        
                                          
                                            
                                              | º´¿ë±Ý±â |  
                                                                  
                                           | 
                                         
                                         |  
                                        
                                          | 
                                            
                                           | 
                                                                               
                                         |  
                                        
                                
                            
                            
                                         |  
                                        
                                          
                                            
                                            
                                                  | 
                                                Á¦Ç°º° ¿¬·É±Ý±â °í½Ã | 
                                             
                                             
                                           | 
                                         
                                         |  
                                        
                                            
                                                
                                                
                                                    | ¼ººÐ¸í | 
                                                    ¼ººÐÄÚµå | 
                                                    ƯÁ¤¿¬·É | 
                                                    °í½Ã¹øÈ£ | 
                                                    °í½ÃÀÏÀÚ | 
                                                    ºñ°í | 
                                                 
                            
                                                
                                                    | dicyclomine hydrochloride | 
                                                    143701ACH | 
                                                    6 °³¿ù ÀÌÇÏ | 
                                                    20130047 | 
                                                    2013-02-25 | 
                                                    ¾ÈÀü¼º ¹× À¯È¿¼º ¹ÌÈ®¸³ | 
                                                 
                                              
                                                 
                                             | 
                                         
                            
                              
                                                        
                              
                                                
                            
 |   
    | 
      
     | 
 
 |  
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
  
  
    
      
  
    
       |  
      
        
          
            
                | Çã°¡Á¤º¸ | 
             
           
         | 
       
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        644600620[A24600151]  
	    
	    
            [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1ĸ½¶(2011.09.01)(ÇöÀç¾à°¡)
            \25 ¿ø/1ĸ½¶(2002.04.09)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
      [Áúº´ÄÚµåÁ¶È¸]
     
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
   
    | Á¦Ç°¼º»ó | 
    Èò»öÀÇ ºÐ¸»ÀÌ µç »ó¡¤ÇÏ ¹ÌȲ»öÀÇ °æÁúĸ½¶Á¦  [Á¦ÇüÁ¤º¸ È®ÀÎ] |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    10 ĸ½¶/ÇÇÆ¼ÇÇ | 
   
  
  
  
   
    | Æ÷À塤ÄÚµå´ÜÀ§ | 
    
        
        
            | ¾àǰ±Ô°Ý | 
            ´ÜÀ§ | 
            Æ÷ÀåÇüÅ | 
            ´ëÇ¥ÄÚµå | 
            Ç¥ÁØÄÚµå | 
            ºñ°í | 
	     
        
        
            | 10¹Ð¸®±×·¥ | 
            10 ĸ½¶ | 
            PTP | 
            8806446006208 | 
            8806446006215 | 
             | 
	     
        
         
     | 
   
      
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      143701ACH  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
   
    | Çã°¡»çÇ× ¿ø¹®Á¶È¸ | 
    
      
	    [Çã°¡»çÇ× ¿ø¹®Á¶È¸] 
     | 
   
  
  
  
  
     
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      ´ÙÀ½ Áúȯ¿¡¼ °æ·Ã ¿ÏÈ : À§¡¤½ÊÀÌÁöÀå±Ë¾ç, À§¿°, ´ëÀå¿°, °Ô½Ç(°çÁÖ¸Ó´Ï)¿°, °æ·Ã¼º º¯ºñ
      
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
  
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
      [󹿾à¾î] 
      ¼ºÀÎ : µð½ÃŬ·Î¹Î¿°»ê¿°À¸·Î¼ 1ȸ 10 ¡ 20 mg 1ÀÏ 3 ¡ 4ȸ º¹¿ëÇÑ´Ù. 
2ÁÖ À̳» Áõ»óÀÌ °³¼±µÇÁö ¾Ê°Å³ª 1ÀÏ 80mg ¹Ì¸¸ÀÇ ¿ë·®¿¡¼ ºÎÀÛ¿ëÀÌ ³ªÅ¸³ª´Â °æ¿ì º¹¿ëÀ» Áß´ÜÇØ¾ß ÇÑ´Ù.
     
      	
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    1) ³ì³»Àå ȯÀÚ 
2) Àü¸³»ùºñ´ë¿¡ ÀÇÇÑ ¹è´¢Àå¾Ö ȯÀÚ 
3) ½ÉÇÑ Áõ»óÀÇ ½ÉÁúȯ ȯÀÚ 
4) Æó¼â¼º ¿ä·ÎÁúȯ ȯÀÚ 
5) À¯¹®ÇùÂø µî À§Àå°üÆó»ö ȯÀÚ 
6) ¸¶ºñ¼º ÀåÆó»ö ȯÀÚ 
7) ÀåÀÇ ¹«±äÀåÁõ ȯÀÚ 
8) ±Þ¼º ÃâÇ÷±âÀÇ ºÒ¾ÈÁ¤ÇÑ ½ÉÇ÷°ü »óÅ ȯÀÚ 
9) ÀÌ ¾à¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ 
10) 6°³¿ù ÀÌÇÏÀÇ ¿µ¾Æ(Á¥¸ÔÀÌ) 
11) ¼öÀ¯ºÎ 
12) ½ÉÇÑ Áõ»ó ±ÙÀ°¹«·ÂÁõ ȯÀÚ 
13) ½ÉÇÑ Áõ»óÀÇ ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ 
14) °Å´ë°áÀå ȯÀÚ 
15) ¿ª·ù¼º ½Äµµ¿° ȯÀÚ 
16) ÀÌ ¾àÀº À¯´ç(Á¥´ç)À» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î, °¥¶ôÅä¿À½º ºÒ³»¼º(galactose intolerance), Lapp À¯´çºÐÇØÈ¿¼Ò °áÇÌÁõ(Lapp lactase deficiency) ¶Ç´Â Æ÷µµ´ç-°¥¶ôÅä¿À½º Èí¼öÀå¾Ö(glucose-galactose malabsorption) µîÀÇ À¯ÀüÀûÀÎ ¹®Á¦°¡ Àִ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¸é ¾È µÈ´Ù. 
 | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    ´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» º¹¿ëÇϱâ Àü¿¡ ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í.
  
1) ÀÚÀ²½Å°æº´Áõ ȯÀÚ 
2) °£¡¤½ÅÁúȯ ȯÀÚ 
3) °íÇ÷¾Ð ȯÀÚ 
4) °©»ó»ù ±â´É Ç×ÁøÁõ ȯÀÚ 
5) Àü¸³»ù ºñ´ë ȯÀÚ 
6) ½É±â´ÉÀå¾Ö(°ü»óµ¿¸ÆÁúȯ, ¿ïÇ÷½ÉºÎÀü, ºÎÁ¤¸Æ µî) ȯÀÚ 
7) °í¿Â ȯ°æ¿¡ Àִ ȯÀÚ 
8) ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ 
9) °í·ÉÀÚ : °í·ÉÀÚ¿¡´Â ÀÌ ¾àÀÇ Ç×Äݸ° ÀÛ¿ëÀ¸·Î ÀÎÇÑ ±¸°¥, ¹è´¢Àå¾Ö, º¯ºñ, ¾È³»¾ÐÇ×Áø µîÀÇ ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. 
10) ÀӺΠ: ÀӺο¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¹× ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º¿¡´Â Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸ(¿ôµº)ÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù. 
11) ¼Ò¾Æ : ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù. 
12) ÀÌ ¾àÀº Ȳ»ö5È£(¼±¼Â¿»·Î¿ì FCF, Sunset Yellow FCF)¸¦ ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î ÀÌ ¼ººÐ¿¡ °ú¹ÎÇϰųª ¾Ë·¹¸£±â º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
 | 
   
  
    
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      ´ÙÀ½°ú °°Àº °æ¿ì ÀÌ ¾àÀÇ º¹¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã½Ã °¡´ÉÇÑÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í.
  
1) ´« : ¶§¶§·Î ½Ã°¢Á¶ÀýÀå¾Ö, µ¿°øÈ®´ë, Èå·Áº¸ÀÓ, ¾È³»¾ÐÇ×Áø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
2) Á¤½Å½Å°æ°è : ¶§¶§·Î µÎÅë, µÎÁß, ¾îÁö·³, Á¹À½, ½Ç½Å µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
3) È£Èí±â°è : È£Èí°ï¶õ, ÄÚ¸·Èû 
4) ¼Òȱâ°è : ±¸°¥, º¯ºñ, ¶§¶§·Î ¼³»ç, ¹±Àºº¯, ±¸¿ª¡¤±¸Åä, º¹ºÎÆØ¸¸, À§ºÎºÒÄè°¨, º¹Åë, ¼ÒȺҷ®, ½Ä¿åºÎÁø µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
5) ¼øÈ¯±â°è : ¶§¶§·Î ½É°èÇ×Áø(µÎ±Ù°Å¸²), ºÎÁ¤¸Æ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
6) °ú¹Î¹ÝÀÀ : ¾ó±¼ºÎÁ¾, Ç÷°üºÎÁ¾, ¾Æ³ªÇʶô½Ã½º¼îÅ© µå¹°°Ô ¹ßÁø, °¡·Á¿ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. 
7) ºñ´¢±â°è : ¶§¶§·Î ¹è´¢Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
8) ±âŸ : ¶§¶§·Î ±Çۨ, ¹«·Â°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
      
     | 
   
        
  
  
  
    
  
  
       	
  
     
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
       
     | 
      
  
  
  |  
     
   
  
    
       |  
      
        
          
            
                | Á¤º¸¿ä¾à |         
             
           
         | 
             	    
       |  
      | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
     
   
  
    
       |  
      
        
          
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |         
             
           
         | 
             	    
       |  
      | 	 |  
     
   
  
    
       |  
      
        
          
            
                | Á¦Ç°Á¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
   
  
    
       |  
      
        
          
            
                | º¹¾àÁ¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Bµî±Þ 
				        
				         (dicyclomine; )
				        
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
    
        | 
      ¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
     
   
  
    
       |  
      
        
          
            
                | ½É»çÁ¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
     
  
    
       |  
      
        
          
            
                | ÇмúÁ¤º¸ |          
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      Á¦ÇÑ¿¬·É±¸ºÐ (6°³¿ù¹Ì¸¸)
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Dicyclomine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic). 
     | 
   
  
   
    | Pharmacology | 
     
       Dicyclomine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Dicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions. 
     | 
   
  
   
    | Protein Binding | 
    
       Dicyclomine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ >99% 
     | 
   
  
   
    | Half-life | 
    
       Dicyclomine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available 
     | 
   
  
   
    | Absorption | 
    
       Dicyclomine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available 
     | 
   
  
   
    | Pharmacokinetics | 
    
       Dicyclomine HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ÀÛ¿ë¹ßÇö½Ã°£ : 1-2½Ã°£
	
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 4½Ã°£±îÁö
	
 - Èí¼ö : °æ±¸ : Àß Èí¼öµÊ
	
 - ºÐÆ÷ : Vd : 3.65 L/kg 
 - ´ë»ç : ´ë»ç Å
	
 - ¹Ý°¨±â 
	
		- Ãʱ⠻ó(phase) : 1.8½Ã°£  
		
 - ¸»±â »ó : 9-10½Ã°£
	
  
	 - ¼Ò½Ç : ¹Ìº¯Èü·Î¼ ¼Ò·®¸¸ÀÌ ´¢¸¦ ÅëÇØ ¹è¼³µÊ
  
 
	
     | 
   
  
   
    | Toxicity | 
    
       Dicyclomine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available 
     | 
   
  
   
    | Drug Interactions | 
    
       Dicyclomine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Donepezil	Possible antagonism of actionGalantamine	Possible antagonism of actionRivastigmine	Possible antagonism of actionHaloperidol	The anticholinergic increases the risk of psychosis and tardive dyskinesia 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Dicyclomine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid alcohol.Take this medication 30 minutes before meals. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Dicyclomine¿¡ ´ëÇÑ Description Á¤º¸ A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Dicyclomine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule	OralSolution	IntramuscularSyrup	OralTablet	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Dicyclomine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anticholinergic AgentsAntimuscarinicsAntispasmodicsMuscarinic AntagonistsParasympatholytics 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Dicyclomine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Dicyclomine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1 
     | 
   
  
   
    | InChI Identifier | 
    
       Dicyclomine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Dicyclomine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate 
     | 
   
    
  |  
     
     
  
    
       |  
      
        
          
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ |           
             
           
         | 
             	  
       |  
       |  
     
         
 
     | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-03-15
              
 
              - 
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
  
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  [ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â]       Á¦¸ñ ¾øÀ½ 
 
    
    2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
    
    1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ  º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
          
    
    
    
    2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
    6°³¿ù¹Ì¸¸/20070030/200700005/20070411 
 
 
 
   
  |  
                           
                         | 
                       
                      | 
                   |